In a mouse model of Alzheimer’s disease (AD), this limited neuroprotective effect of long-term irreversible MAO-B inhibitor treatment was attributed to short-lived action due to a rebound in astrocytic GABA accumulation through a diamine oxidase (DAO)-mediated compensatory mechanism [9, 14]. Here, MAOB is linked to Alzheimer disease.